Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Healthy
Interventions: 5 mg/500 mg METAGLIP™ Tablets, 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Healthy
Interventions: Metformin Hydrochloride ER Tablets 500 mg, Glucophage® XR Tablets 500 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Dietary Fats, Pharmacokinetics
Interventions: Regorafenib (Stivarga, BAY73-4506); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Brighton, Massachusetts

Conditions: Amyotrophic Lateral Sclerosis
Interventions: GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more

Conditions: Strep Throat
Interventions: Preview Rapid Strep A test; Diagnostic Test
Lead sponsor: Guangzhou Wondfo Biotech Co., Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Johnson City, New York • Liverpool, New York

Conditions: Multiple Myeloma
Interventions: Opaganib; Drug
Lead sponsor: RedHill Biopharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy Volunteers
Interventions: LY2157299; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Primary CNS Lymphoma, Refractory Primary CNS Lymphoma, Relapsed Primary CNS Lymphoma
Interventions: Tisagenlecleucel; Biological
Lead sponsor: Matthew J. Frigault, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatic Impairment
Interventions: Nalbuphine ER; Drug
Lead sponsor: Trevi Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida

Conditions: Primary Open-angle Glaucoma (POAG) Patient
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 40 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity
Interventions: Low-Carbohydrate Diet, Intermittent Energy Restriction, Hunger Training; Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: ECT, Treatment Resistant Depression
Interventions: Electroencephalographic (EEG), Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR16), Ictal Electroencephalographic (EEG) Measurements, Post-Ictal Electroencephalographic (EEG) Suppression Measurements; Diagnostic Test
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioma
Interventions: capecitabine [Xeloda]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 3 Years to 21 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 6 more

Conditions: Isolated Impaired Fasting Glucose
Interventions: Low-calorie diet, Routine dietary and physical activity habits; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 35 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Dehydration, Menstruation, Pre-menopause, Peri-menopausal Women, Post-menopausal Women, Hydration
Interventions: placebo beverage, electrolyte beverage; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Bradenton, Florida • Valhalla, New York

Conditions: Pharmacokinetics
Interventions: Theophylline 300mg, Quinine 648 mg, Theophylline 300 mg; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Ulcerative Colitis
Interventions: A plant based high fiber diet that mimics fasting ("FMD") plus advanced therapy, Advanced therapy only without dietary intervention; Other · Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Hypertriglyceridemia, Diabetes Mellitus
Interventions: Low Fat/High Carbohydrate, High Monounsaturated Fat/Low Carbohydrate; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Critical Illness, Surgical Procedure, Unspecified, Pulmonary Aspiration, Fasting
Interventions: Fasting, Not fasting; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 1,072 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Palo Alto, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Talaromycosis
Interventions: Liposomal Amphotericin B (LAmB), Flucytosine (5FC), Flucytosine (5FC) placebo pill, Deoxycholate Amphotericin B (DAmB); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: IV Drug Usage, HIV Infections, Hepatitis C
Interventions: Tele-Harm Reduction, off-site linkage; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Miami, Florida • Tampa, Florida

Conditions: Recurrent Respiratory Papillomatosis
Interventions: Human Papillomavirus Vaccine; Biological
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Stress, Carer Stress Syndrome, Dementia, Alzheimer Disease
Interventions: Biofeedback Training, Dementia Education, Resourcefulness Training; Behavioral · Other
Lead sponsor: Case Western Reserve University; Other
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastrointestinal Stromal Tumors
Interventions: CGT9486, Pexidartinib, Sunitinib; Drug
Lead sponsor: Cogent Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 6
States / cities: Miami, Florida • Boston, Massachusetts • Ann Arbor, Michigan + 3 more

Search by objective public record fields.

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

Fasting BE Study of Metformin Hydrochloride ER Tablets 500 mg and Glucophage® XR Tablets 500 mg

The Effect of Food (High Fat and Low Fat Breakfast) on the Pharmacokinetics of Regorafenib

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

Preview Rapid Strep A Test Method Comparison Study

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

A Study of LY2157299 in Healthy Participants

Tisagenlecleucel In Primary CNS Lymphoma

Study of Nalbuphine ER in Participants With Hepatic Impairment

Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients

Testing the Effect of Multiple Weight Management Modalities for Chronic Disease Risk Reduction in a Clinical Setting

CET- REM (Correlating ECT Response to EEG Markers)

A Study of Xeloda (Capecitabine) Plus Radiation Therapy in Children With Newly Diagnosed Gliomas

Low-calorie Diet in Isolated Impaired Fasting Glucose

Hydration & Female Life Stages

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis

Effect of Changing Diet on Fasting and Post Fat Load Lipoproteins

Preoperative Fasting vs. Not Fasting in Critically Ill Patients

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Tele-Harm Reduction

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

Tailored Health Self-Management Interventions for Highly Distressed Caregivers: Family Members of Persons With Dementia

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors